RADX

By John Vandermosten, CFA NASDAQ: RADX READ THE FULL RADX RESEARCH REPORT Fiscal 3Q:26 Activity and Cash Flows Radiopharm Theranostics (NASDAQ: RADX) released its Quarterly Activities and Cash Report for its third quarter ending March 31st, 2026. Beyond the review of cash sources and uses for the first nine months of fiscal year 2026, the report summarizes the status of each of the company’s pipeline assets. Since the previous quarterly financial update, Radiopharm presented a second set of interim data for its RAD101 imaging agent and advanced RAD202 to the next dose level. Two Phase I trials were started: RV01 as part of the Radiopharm Ventures collaboration and RAD402 in advanced prostate cancer. We include our previously published summary of the RAD101 second interim data analysis, followed by an update on Radiopharm’s other programs. Financial Performance During its third quarter, Radiopharm’s operating activities consumed $14.9 million for the three-month period ending March 31st, 2026. Cash used in financing activities was $284,000 for the same three-month period.[1] For the fiscal third quarter: There were $443,000 in cash receipts from customers; Research and development consumed $11.8 million related to the management of multiple clinical trials; Advertising and marketing costs consumed $108,000; Staff costs consumed $2.4 million; Administration and corporate costs were $1.6 million; Interest received totaled $152,000; Other miscellaneous cash operating contributions, consisting of interest and Goods and Services Tax (GST) refunds, total $554,000; No cash flows categorized as investing activities were recognized; Cash used in financing activities was $284,000 related to transaction costs from securities issuance. As of March 31st, 2026, Radiopharm held $19.2 million in cash compared to $19.0 million at the end of FY:25 last June. Cash burn for 3Q:26 was $14.9 million, while cash burn for the first nine months of the fiscal year was $37.6 million. Radiopharm is expecting over $8 million over the next four months from tax rebates and also has an at-the-money (ATM) facility in place with Leerink Partners with capacity of up to US$50 million to support capital needs until 2028. Corporate Milestones[2] Ownership increase in Radiopharm Ventures (RV01) to 87.5% - January 2026 RAD101 Phase II trial fully enrolled – February 2026 RV01 first patient dosed in...

By John Vandermosten, CFA NASDAQ:RADX READ THE FULL RADX RESEARCH REPORT Radiopharm Theranostics (NASDAQ:RADX) released its first half 2026 cash flow statement on January 28th, 2026. The company has a June 30 fiscal year end and reports audited financial statements semiannually. We expect the half year report, prepared under International Financial Reporting Standards (IFRS), to be issued next month. The period captured in this report is from July 1st to December 31st 2025. Beyond the review of cash sources and uses for the first half of fiscal year 2026, the report summarizes the status of each of the company’s pipeline assets. Since the previous financial update, Radiopharm has presented interim data for its RAD101 imaging agent and reiterated upcoming milestones for RAD202 and RAD204, and anticipated delivery of data. Radiopharm’s operating activities consumed ($22.7) million for the six-month period ending December 31st, 2025. Cash from financing activities was $33.4 million for the same six-month period.[1] For the first six months of the reporting period ending December 31st, 2025: There were no cash receipts from customers; Research and development consumed ($19.4) million related to the management of multiple clinical trials; Advertising and marketing costs consumed ($228,000); Staff costs consumed ($6.3) million; Administration and corporate costs were ($1.9) million; Other miscellaneous cash operating contributions total $5.1 million, mostly impacted by $4.5 million in government grants and tax incentives; Other payments categorized as investing activities consumed ($5.3) million for payments of license fees; Financing cash was $33.4 million from the issuance of equity securities, partially offset by transaction costs. As of December 31st, 2025, Radiopharm held $34.5 million in cash compared to $19.0 million at the end of FY:25. Cash burn for 1H:26 was ($28.0) million. RAD101 Phase IIb Interim Analysis Radiopharm Theranostics reported the primary endpoint for its RAD101 trial in an interim analysis on December 15th. Following the release, management held a webcast which featured the company’s CEO, Riccardo Canevari, Chief Medical Officer Dr. Dimitris Voliotis, and the principal investigator on the RAD101 trial, Dr. Harshad Kulkarni. Topline from the release indicated that 92% (11/12) of evaluated patients treated with RAD101 achieved concordance wi...

Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026 Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milestones SYDNEY, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced financial results for the first six months of fiscal 2026 ended December 31, 2025 and provided an update on its clinical pipeline with an outline of its expected milestones for 2026. “2025 was a year of strong execution across our pipeline, as we presented unprecedented imaging data from our RAD 101 diagnostic program, received Data Safety Monitoring Committee approval to escalate dosing in both RAD 204 and RAD 202 programs and secured clearance to advance both RV 01 and RAD 402 into Phase 1 clinical trials,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “As we enter 2026, we remain laser-focused on advancing our radiopharmaceutical assets and taking a deliberate approach to pipeline prioritization. This year, we aim to deliver meaningful data from across multiple programs, expand treatment and diagnostic options for patients with solid tumors, and create long-term value for all stakeholders.” Program and Business Updates 18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled with Fluorine-18 RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of the molecule in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins. RAD 101 has received U.S. Food and Drug Administration (FDA) Fast Track Designation to expedite the review process and help bring the novel imaging small molecule to the over 300,000 patients diagnosed annually in the U.S. with cerebral metastases. The study is currently enrolling patients and anticipates completing enroll...

Net loss: AU$38.3m (loss narrowed by 20% from FY 2024). AU$0.018 loss per share (improved from AU$0.12 loss in FY 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Phase III: 3. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 75%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Looking ahead, revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Biotechs industry in Australia. Performance of the Australian Biotechs industry. The company's share price is broadly unchanged from a week ago. We should say that we've discovered 3 warning signs for Radiopharm Theranostics (1 is a bit concerning!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177 On track to complete enrollment of the first cohort of Phase 1 ‘HEAT’ trial of RAD202 for treatment of advanced HER2-positive solid tumors U.S. FDA granted Fast Track Designation for RAD101 to distinguish between recurrent disease and the treatment effect of brain metastases Confirmed guidance of Cash Runway through to mid-2026 SYDNEY, Australia, July 29, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced financial results for the fiscal year ended June 30, 2025, and provided a corporate update. “During the last quarter, we continued to execute with discipline and momentum across our pipeline, advancing key milestones within both our therapeutic and diagnostic radiopharmaceutical programs,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “We are encouraged by the pace and efficiency of our development efforts. Notable achievements this quarter include the FDA’s Fast Track Designation for RAD101, DSMC clearance to proceed with higher dosing of RAD204, procurement of multiple supply agreements for key radioisotopes and meaningful clinical progress across our clinical pipeline. These milestones reflect our unwavering commitment to delivering precise, targeted radiopharmaceutical solutions that have the potential to transform cancer care. Looking ahead, we anticipate a number of important clinical and corporate milestones throughout the remainder of 2025.” Program and Business Updates 177Lu-RAD204 – Nanobody targeting PD-L1 radiolabeled with Lutetium 177 In May 2025, Radiopharm shared updates from an independent Data and Safety Monitoring Committee (DSMC), which concluded that Cohort 2 of the Phase 1 study of 177Lu-RAD204 could proceed at a higher dose level. The higher dose level was determined to be 60mCi of Lu177 rather than the 40mCi previously assumed in the protocol. The second cohort of patients is expected to be fully enrolled in the coming weeks and will include expansion to multiple tumor types including Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Triple-Negative B...